VP2-2022: Prospective double-blind, randomized phase III ENGOT-EN5/GOG-3055/SIENDO study of oral selinexor/placebo as maintenance therapy after first-line chemotherapy for advanced or recurrent endometrial cancer.

Authors :: Vergote, I.B.
Fidalgo, A. Pérez
Hamilton, E.
Valabrega, G.
Van Gorp, T.
Sehouli, J.
Cibula, D.
Levy, T.
Welch, S.
Richardson, D.L.
Alía, E.M. Guerra
Scambia, G.
Henry, S.
Wimberger, P.
Miller, D.
Martínez, J.
Monk, B.J.
Shacham, S.
Mirza, M.R.
Makker, V.
Source :: Annals of Oncology. Apr2022, Vol. 33 Issue 4, p448-450. 3p.
Publication Year :: 2022

Full Text Access

Tools